Tag Archive for: Brian Dolan

Report: Patient monitoring worth $9.3 billion in 2014

And more reports that we are headed in the right direction!!!  Remote Monitoring is minimizing hospital stays, saving money!!!

By: Brian Dolan | May 18, 2011 8:22pm EST

Tags:  |  |  |  | |  |  |


According to a new report from TechNavio, the global patient monitoring system market will swell to $9.3 billion in 2014. TechNavio’s analysis focuses on the US, EMEA and APAC and concludes that remote patient monitoring is driving growth in the wider patient monitoring market. The price of these systems is cost prohibitive, however, the report found.

“Remote Patient Monitoring (RPM) is greatly minimizing hospital stays, resulting in a reduction of the cost of healthcare delivery. Thus, RPM helps healthcare centers reduce costs and increase business opportunities for healthcare service providers while integrating systems and providing necessary operational facilities. As a result, the Patient Monitoring Systems market stands to gain,” TechNavio states in a press release.

Earlier this year Kalorama Information predicted that the market for remote and wireless patient monitoring will grow about 26 percent annually through 2014. Kalorama said the market for these systems will grow by over $6 billion this year alone, which seems to put it at odds with TechNavio’s $9.3 billion by 2014 figure.

The disagreement doesn’t end there, of course. Plenty of opinions on market size:

Late last year in December, we reported on Berg Insight’s market size estimation for home health monitoring of what it called “welfare diseases,” which it pegged at about $10 billion in 2010. That figure included the market for chronic condition management for conditions including diabetes, cardiac arrhythmia, sleep apnea, asthma and chronic obstructive pulmonary disease (COPD).

Perhaps this kind of figure is more important: In 2010 we reported on Juniper Research’s estimate that by the year 2014 public and private healthcare providers may save between $1.96 billion and $5.83 billion in healthcare costs thanks to remote patient monitoring over cellular networks.

For more on the TechNavio report, read the press release below:

ROCKVILLE, MD — MarketResearch.com has announced the addition of Infiniti Research Limited’s new report “Global Patient Monitoring Systems Market 2010-2014,” to their collection of Medical Devices market reports.

Patient Monitoring Systems Market Witnesses Growth in Remote Monitoring Research conducted by TechNavio reveals that the Global Patient Monitoring System market will reach $9.3 billion in 2014. The report, which focuses on United States, EMEA, and APAC, indicates that the market is currently driven by the growth in remote patient monitoring.

“Remote Patient Monitoring (RPM) is greatly minimizing hospital stays, resulting in a reduction of the cost of healthcare delivery. Thus, RPM helps healthcare centers reduce costs and increase business opportunities for healthcare service providers while integrating systems and providing necessary operational facilities. As a result, the Patient Monitoring Systems market stands to gain,” report TechNavio analysts.

In spite of the demand for these systems, the high price of these systems hinders the growth of this market. However, the growth opportunities in Europe and APAC are expected to drive the market.

The Global Patient Monitoring Systems market is marked by the slow recovery of the North American market. This makes the study an important one for companies to fully understand the potential in the market and formulate their own strategy.

The report, Global Patient Monitoring System 2010-2014, is based on extensive research and inputs from industry experts, vendors, and end users. It examines the factors impacting the evolution of this market, including the key trends, drivers, and challenges. Further, it contains an in-depth understanding of the key vendors including a SWOT analysis for each vendor.

Companies mentioned in this report include: Philips Healthcare, GE Healthcare, Omron Healthcare, Drager Medical Gmbh, and Johnson and Johnson.

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6315506

Investor: Health tech is next big opportunity

By Don Ross, Managing Director & Founder, HealthTech Capital

Early-stage investors in traditional healthcare companies are certainly having a tough time these days. Many biotech, diagnostic and medical device firms have simply become too risky, as the current uncertain FDA regulatory environment increases cost and time to exit. In fact, venture funding for these companies fell during the fourth quarter of 2010 to the lowest level since 2003, and the number of deals dropped further in the first quarter of 2011, according to PricewaterhouseCoopers.

This overhanging “exit challenge” is leading many angel investors and venture capitalists to seek new types of investments – companies with lower capital requirements and faster exits. Nowhere was this quest more evident than at the 2011 Angel Capital Association Summit, a premier angel investor event, held last month in Boston.

During the event, I participated on the “Future of Life Science Investing” panel, where the discussion quickly left traditional life sciences and zeroed in on what is emerging as the next big investment opportunity arena: healthtech.

Don Ross is managing director and founder of HealthTech Capital, an angel investing group that funds and mentors early-stage companies in the emerging healthtech domain.

Healthtech companies use mobile, cloud, and other information technologies to increase healthcare delivery efficiencies and deliver consumer-centric applications. Unlike traditional “health IT,” healthtech companies target applications everywhere along spectrum of health and wellness—from in-hospital workflow to in-home monitoring to consumer wellness applications.

Healthtech markets are propelled by technical advancements, an aging population, and government regulations and subsidies to drive adoption of electronic medical records. And, although the FDA is turning its attention to healthtech, most companies in this sector are expected to face comparatively low regulatory requirements.

How big is the healthtech opportunity? Data from the Centers for Medicare & Medicaid Services (CMS) show that the U.S. spent $2.5 trillion on health care in 2009. Of this, 84 percent was spent on healthcare delivery, which includes costs associated with clinicians and insurance companies. In contrast, only 16 percent was spent on therapeutics, including medical devices and drugs. Although venture investors traditionally have put their money into therapeutics rather than delivery, the balance is shifting.

In fact, healthtech was a “star” topic at the recent J.P. Morgan Annual Healthcare Conference in San Francisco, where panelists included Eric Schmidt, Google’s then-CEO, and other technologists not typically associated with health care. Further evidence of the shift in investor attention towards healthtech is the recent establishment of HealthTech Capital, the first angel investing group to focus exclusively on this space. Barely a year old, the group’s membership already is larger than many long-established angel groups and includes individual investors, VCs, corporate venture arms, and healthcare providers.

Healthtech is a complex domain, with several factors that can make or break a company. Existing contracts and relationships may have locked up a market segment. Standards of proof are much higher than in the tech world. Lack of reimbursement can kill a company. A sale often must address a multi-part customer with separate value propositions for the patient, doctor, hospital, and insurance company. Improving patient care alone is insufficient. One physician put his requirements for new technologies to me succinctly: “Will I get paid, and will I get sued?”

Read more